BR112023022315A2 - Quimeras direcionadas à desubiquitinase e métodos relacionados - Google Patents
Quimeras direcionadas à desubiquitinase e métodos relacionadosInfo
- Publication number
- BR112023022315A2 BR112023022315A2 BR112023022315A BR112023022315A BR112023022315A2 BR 112023022315 A2 BR112023022315 A2 BR 112023022315A2 BR 112023022315 A BR112023022315 A BR 112023022315A BR 112023022315 A BR112023022315 A BR 112023022315A BR 112023022315 A2 BR112023022315 A2 BR 112023022315A2
- Authority
- BR
- Brazil
- Prior art keywords
- chimeras
- related methods
- desubiquitinase
- targeting
- well
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181796P | 2021-04-29 | 2021-04-29 | |
| US202163186739P | 2021-05-10 | 2021-05-10 | |
| US202163273118P | 2021-10-28 | 2021-10-28 | |
| US202263311781P | 2022-02-18 | 2022-02-18 | |
| PCT/US2022/027120 WO2022232634A1 (en) | 2021-04-29 | 2022-04-29 | Deubiquitinase-targeting chimeras and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023022315A2 true BR112023022315A2 (pt) | 2024-02-20 |
Family
ID=81748638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023022315A BR112023022315A2 (pt) | 2021-04-29 | 2022-04-29 | Quimeras direcionadas à desubiquitinase e métodos relacionados |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240252655A1 (enExample) |
| EP (1) | EP4329815A1 (enExample) |
| JP (1) | JP2024515828A (enExample) |
| KR (1) | KR20240004584A (enExample) |
| CN (1) | CN120225225A (enExample) |
| AU (1) | AU2022265718A1 (enExample) |
| BR (1) | BR112023022315A2 (enExample) |
| CA (1) | CA3216614A1 (enExample) |
| IL (1) | IL307863A (enExample) |
| MX (1) | MX2023012852A (enExample) |
| WO (1) | WO2022232634A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024220874A2 (en) * | 2023-04-21 | 2024-10-24 | Icahn School Of Medicine At Mount Sinai | Otub1 small-molecule binders and otub1-recruiting deubiquitinase-targeting chimeras (dubtacs) |
| WO2024233280A1 (en) * | 2023-05-05 | 2024-11-14 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional small molecules that deubiquitinylate and stabilize target proteins by recruiting usp7 |
| WO2024264072A2 (en) * | 2023-06-23 | 2024-12-26 | Stablix, Inc. | Parp inhibitors |
| CN119350422B (zh) * | 2024-12-25 | 2025-04-04 | 中国药科大学 | 一种去泛素化酶靶向嵌合体化合物及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008109031A (ru) | 2005-08-11 | 2009-09-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы муковисцидозного трансмембранного регулятора проводимости |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| PL2168966T3 (pl) | 2007-06-15 | 2017-06-30 | Msd K.K. | Pochodna bicykloaniliny |
| CN102743385B (zh) * | 2007-11-16 | 2014-09-17 | 沃泰克斯药物股份有限公司 | Atp结合盒转运蛋白的异喹啉调节剂 |
| US20110035601A1 (en) | 2007-12-21 | 2011-02-10 | University Of Virginia Patent Foundation | System, method and computer program product for protecting software via continuous anti-tampering and obfuscation transforms |
| EP2303885B1 (en) | 2008-06-12 | 2013-07-03 | Merck Sharp & Dohme Corp. | Process for producing bicycloaniline derivatives |
| CZ2009620A3 (cs) | 2009-09-22 | 2011-04-06 | Ústav makromolekulární chemie AV CR, v.v.i. | Surovina pro výrobu polyurethanu a zpusob její výroby z odpadního polyurethanu |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| WO2011133953A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| KR20150097660A (ko) | 2012-12-19 | 2015-08-26 | 노파르티스 아게 | Cftr 채널을 억제하기 위한 트리시클릭 화합물 |
| CA2895656A1 (en) | 2012-12-19 | 2014-06-26 | Novartis Ag | Tricyclic compounds as cftr inhibitors |
| WO2018037350A1 (en) | 2016-08-23 | 2018-03-01 | Laurus Labs Limited | Solid forms of lumacaftor, process for its preparation and pharmaceutical compositions thereof |
| CA3103205A1 (en) * | 2018-06-13 | 2019-12-19 | Amphista Therapeutics Ltd | Bifunctional molecules for targeting uchl5 |
| WO2020069105A1 (en) * | 2018-09-27 | 2020-04-02 | Dana-Farber Cancer Institute, Inc. | Degraders of wee1 kinase |
| AU2020224327B2 (en) * | 2019-02-21 | 2022-09-29 | Entact Bio Limited | Survival-targeting chimeric ( SURTAC) molecules |
| EP4090371A4 (en) * | 2020-01-14 | 2024-04-03 | The Trustees of Columbia University in the City of New York | COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY RE-ROUTING ENDOGENOUS DEUBIQUITINASES |
-
2022
- 2022-04-29 CA CA3216614A patent/CA3216614A1/en active Pending
- 2022-04-29 AU AU2022265718A patent/AU2022265718A1/en active Pending
- 2022-04-29 KR KR1020237040245A patent/KR20240004584A/ko active Pending
- 2022-04-29 IL IL307863A patent/IL307863A/en unknown
- 2022-04-29 BR BR112023022315A patent/BR112023022315A2/pt unknown
- 2022-04-29 US US18/288,550 patent/US20240252655A1/en active Pending
- 2022-04-29 WO PCT/US2022/027120 patent/WO2022232634A1/en not_active Ceased
- 2022-04-29 JP JP2023566513A patent/JP2024515828A/ja active Pending
- 2022-04-29 EP EP22724358.1A patent/EP4329815A1/en active Pending
- 2022-04-29 CN CN202280032073.1A patent/CN120225225A/zh active Pending
- 2022-04-29 MX MX2023012852A patent/MX2023012852A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4329815A1 (en) | 2024-03-06 |
| CA3216614A1 (en) | 2022-11-03 |
| CN120225225A (zh) | 2025-06-27 |
| MX2023012852A (es) | 2024-01-15 |
| US20240252655A1 (en) | 2024-08-01 |
| WO2022232634A1 (en) | 2022-11-03 |
| JP2024515828A (ja) | 2024-04-10 |
| IL307863A (en) | 2023-12-01 |
| AU2022265718A1 (en) | 2023-11-02 |
| KR20240004584A (ko) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022025061A2 (pt) | Compostos que estabelecem como alvo brm e métodos de uso associados | |
| CL2021003373A1 (es) | Nuevos inhibidores de egfr | |
| MX2021014455A (es) | Inhibidores de proteina cinasas dependientes de adn. | |
| CO2021009695A2 (es) | Conjugados de il-2 y métodos de uso de este | |
| BR112021020285A2 (pt) | Métodos e composições para degradação de proteína alvejada | |
| BR112021019465A2 (pt) | Compostos que têm como alvo prmt5 | |
| CO2021016504A2 (es) | Inhibidores de cdk | |
| MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
| BR112017007769A2 (pt) | compostos e composições para modulação de atividades de cinase de egfr mutante | |
| CO2021001277A2 (es) | Inhibidores de triazol glicolato oxidasa | |
| CO2022001814A2 (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos | |
| MX391414B (es) | Compuesto novedoso de bifenilo o sal del mismo. | |
| EA202190681A1 (ru) | Амиды диметиламиноазетидина в качестве jak ингибиторов | |
| MX2022002667A (es) | Composicion oftalmica para el tratamiento de uveitis. | |
| MX2021015188A (es) | Moduladores de nueva generacion del estimulador de genes de interferon (sting). | |
| BRPI0806789B8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| MX2024005714A (es) | Lípidos catiónicos ionizables para la administración de arn. | |
| CO2024006269A2 (es) | Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos | |
| BR112022012278A2 (pt) | Combinações | |
| MX2023012852A (es) | Quimeras que tienen como diana la desubiquitinasa y metodos relacionados. | |
| BR112019004254A2 (pt) | inibidores da dopamina-b-hidroxilase penetrantes da barreira hematoencefálica | |
| MX2021000935A (es) | Composiciones y metodos terapeuticos para el tratamiento de cancer pancreatico con acido 6,8-bis(bencilsulfanil)octanoico. | |
| CY1123406T1 (el) | Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας | |
| BR112022000297A2 (pt) | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos | |
| CL2021000592A1 (es) | Método para producir un arenavirus antitumoral así como mutantes de arenavirus |